These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 21452026)

  • 41. Teriparatide or alendronate in glucocorticoid-induced osteoporosis.
    Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R
    N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Teriparatide in the management of osteoporosis.
    Bodenner D; Redman C; Riggs A
    Clin Interv Aging; 2007; 2(4):499-507. PubMed ID: 18225450
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Orthopedic uses of teriparatide.
    Bukata SV; Puzas JE
    Curr Osteoporos Rep; 2010 Mar; 8(1):28-33. PubMed ID: 20425088
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.
    Leder BZ; Neer RM; Wyland JJ; Lee HW; Burnett-Bowie SM; Finkelstein JS
    J Clin Endocrinol Metab; 2009 Aug; 94(8):2915-21. PubMed ID: 19435827
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Treatment with recombinant parathyroid hormone of advanced osteoporosis--series of cases].
    Skiba K; Adamczak M; Wiecek A
    Przegl Lek; 2011; 68(7):391-5. PubMed ID: 22010479
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Baseline characteristics of postmenopausal women with osteoporosis treated with teriparatide in a real-world setting in Latin America: a subregional analysis from the Asia and Latin America Fracture Observational Study (ALAFOS).
    Cunha-Borges JL; Mier GM; Casas N; Medina A; Molina JF; García ML; Oliveria LG; Caselato MS; Cruz AC; Ippolito V; Flórez S
    Adv Rheumatol; 2019 Nov; 59(1):46. PubMed ID: 31703737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Osteoanabolic and dual action drugs.
    Tabacco G; Bilezikian JP
    Br J Clin Pharmacol; 2019 Jun; 85(6):1084-1094. PubMed ID: 30218587
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
    Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
    Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and efficacy of teriparatide treatment for severe osteoporosis in patients with Duchenne muscular dystrophy.
    Nasomyont N; Keefe C; Tian C; Hornung L; Khoury J; Tilden JC; Hochwalt P; Jackson E; Rybalsky I; Wong BL; Rutter MM
    Osteoporos Int; 2020 Dec; 31(12):2449-2459. PubMed ID: 32676823
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Evidence in the treatment of osteoporosis using weekly teriparatide injections].
    Nakamura Y
    Clin Calcium; 2012 Mar; 22(3):407-13. PubMed ID: 22370308
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials.
    Han SL; Wan SL
    Int J Clin Pract; 2012 Feb; 66(2):199-209. PubMed ID: 22257045
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Anabolic therapy for osteoporosis: parathyroid hormone.
    Cosman F
    Curr Osteoporos Rep; 2005 Dec; 3(4):143-9. PubMed ID: 16303114
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Combined Pharmacologic Therapy in Postmenopausal Osteoporosis.
    Shen Y; Gray DL; Martinez DS
    Endocrinol Metab Clin North Am; 2017 Mar; 46(1):193-206. PubMed ID: 28131133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of 1 year of daily teriparatide treatment on iliacal bone mineralization density distribution (BMDD) in postmenopausal osteoporotic women previously treated with alendronate or risedronate.
    Misof BM; Paschalis EP; Blouin S; Fratzl-Zelman N; Klaushofer K; Roschger P
    J Bone Miner Res; 2010 Nov; 25(11):2297-303. PubMed ID: 20683883
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial.
    Bhandari M; Jin L; See K; Burge R; Gilchrist N; Witvrouw R; Krohn KD; Warner MR; Ahmad QI; Mitlak B
    Clin Orthop Relat Res; 2016 May; 474(5):1234-44. PubMed ID: 26932738
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of treatments for postmenopausal osteoporosis (bisphosphonates, parathyroid hormone, strontium ranelate, and denosumab) on bone quality: a systematic review.
    Gallacher SJ; Dixon T
    Calcif Tissue Int; 2010 Dec; 87(6):469-84. PubMed ID: 20872215
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Effect of Vibration Treatments Combined with Teriparatide or Strontium Ranelate on Bone Healing and Muscle in Ovariectomized Rats.
    Komrakova M; Hoffmann DB; Nuehnen V; Stueber H; Wassmann M; Wicke M; Tezval M; Stuermer KM; Sehmisch S
    Calcif Tissue Int; 2016 Oct; 99(4):408-22. PubMed ID: 27272029
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cost effectiveness of teriparatide as a first-line treatment for glucocorticoid-induced and postmenopausal osteoporosis patients in Sweden.
    Murphy DR; Smolen LJ; Klein TM; Klein RW
    BMC Musculoskelet Disord; 2012 Oct; 13():213. PubMed ID: 23110626
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Spotlight on teriparatide in osteoporosis.
    Blick SK; Dhillon S; Keam SJ
    BioDrugs; 2009; 23(3):197-9. PubMed ID: 19627171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.